Background: Noncultured epidermal cell transplantation in vitiligo permits the coverage of relatively large areas without culturing cells. Objective: To investigate the effectiveness of noncultured epidermal cell transplantation in treating stabilized vitiligo using objective and subjective evaluation methods. Methods: Noncultured autologous melanocytes and keratinocytes were grafted in a hyaluronic-acid-enriched suspension on superficially laser-abraded vitiligo lesions in 40 patients with refractory stable vitiligo (30 with generalized and 10 with localized vitiligo). The repigmentation was evaluated 3–12 months after grafting using a digital image analysis system. Furthermore the treatment was evaluated from the patients’ point of view with the DLQI (Dermatology Life Quality Index) and a ‘global assessment’. Results: The mean percentage of repigmentation, evaluated at the last follow-up visit, was 72% (median 84%), and a repigmentation of ≧70% was observed in 62% of patients. The best results were achieved in the neck and the presternal region. A subjective evaluation was performed in half of the subjects. The mean DLQI score at inclusion (6.95, SD = 6.68, n = 20) was significantly decreased after treatment (p = 0.013, mean 3.85, SD = 4.13, n = 20). The patients were satisfied with the achieved result, found it worthwhile to undergo the treatment and would choose it again. Conclusion: According to both subjective and objective evaluation methods, noncultured epidermal cell transplantation is promising in patients with stable vitiligo.

1.
Kent G, al-Abadie M: Factors affecting responses on Dermatology Life Quality Index items among vitiligo sufferers. Clin Exp Dermatol 1996;21:330–333.
2.
Van Geel N, Ongenae K, Naeyaert JM: Surgical techniques for vitiligo: a review. Dermatology 2001;202:162–166.
3.
Malakar S, Lahiri K: Punch grafting for lip leucoderma. Dermatology 2004;208:125–128.
4.
Gauthier Y, Surleve-Bazeille JE: Autologous grafting with noncultured melanocytes: a simplified method for treatment of depigmented lesions. J Am Acad Dermatol 1992;26:191–194.
5.
Olsson MJ, Juhlin L: Leucoderma treated by transplantation of a basal cell layer enriched suspension. Br J Dermatol 1998;138:644–648.
6.
Van Geel N, Ongenae K, De Mil M, Naeyaert JM: Modified technique of autologous noncultured epidermal cell transplantation for repigmenting vitiligo: a pilot study. Dermatol Surg 2001;27:873–876.
7.
Van Geel N, Ongenae K, De Mil M, Vander Haeghen Y, Vervaet C, Naeyaert JM: Double-blind placebo-controlled study of autologous transplanted epidermal cell suspensions for repigmenting vitiligo. Arch Dermatol 2004;140:1203–1208.
8.
Olsson MJ, Juhlin L: Long-term follow-up of leukoderma patients treated with transplants of autologous cultured melanocytes, ultrathin epidermal sheets and basal cell layer suspension. Br J Dermatol 2002;147:893–904.
9.
Finlay AY, Khan GK: Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210–216.
10.
Yamaguchi Y, Itami S, Watabe H, Yasumoto K, Abdel-Malek ZA, Kubo T, Rouzaud R, Tanemura A, Yoshikawa K, Hearing VJ: Mesenchymal-epithelial interactions in the skin: increased expression of Dickkopf1 by palmoplantar fibroblasts inhibits melanocyte growth and differentiation. J Cell Biol 2004;26:165:275–285.
11.
Van Geel N, Ongenae K, Vander Haeghen Y, Naeyaert JM: Autologous transplantation techniques for vitiligo: how to evaluate treatment outcome. Eur J Dermatol 2004;14:46–51.
12.
Ongenae K, van Geel N, De Schepper S, Naeyaert JM: Effect of vitiligo on self-reported health-related quality of life. Br J Dermatol 2005;152:1165–1172.
13.
Ongenae K, Dierckxsens L, Brochez L, van Geel N, Naeyaert JM: Quality of life and stigmatization profile in a cohort of vitiligo patients and the effect of the use of camouflage. Dermatology 2005;210:279–285.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.